The Evolving Landscape of Immunotoxicity: Charting Mechanisms and Future Strategies for Immune Checkpoint Inhibitor Adverse Events
Med Research · 2025-12 · 1 (3) · 322-358
DOI: 10.1002/mdr2.70019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Med Research, online erschienen am 29.07.2025. Verfasst von Anqi Lin und 8 weiteren Autor:innen. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 340 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
The use of immune checkpoint inhibitors (ICIs) has significantly improved the efficacy of cancer therapy, but their associated immune‐related adverse events (irAEs) can severely compromise treatment safety. This review systematically summarizes the core mechanisms underlying irAEs, which include multi‐organ damage resulting from T‐cell dysfunction, B‐cell‐mediated autoantibody abnormalities, cytokine network dysregulation, and monocyte‐driven inflammatory cascades. Identified risk factors encompass a range of elements, including host clinical characteristics and underlying diseases, gut microbiota dysbiosis, characteristics of the treatment regimen, tumor type and its histological features, genetic factors and immunogenetic polymorphisms, pre‐existing autoimmune conditions or a history of autoimmunity, and a history of previous exposures alongside various environmental factors. The grading criteria, their clinical context and incidence rates, and clinical management strategies for irAEs affecting various organ systems are detailed herein. Future research should aim to deeply analyze the shared mechanisms and temporal dynamics between irAEs and anti‐tumor effects, develop targeted irAE prediction and monitoring systems, and optimize strategies for irAE prevention and treatment.
Zitieren
APA
Lin, A., Zheng, K., Jiang, A., Huang, X., Wang, Q., Hajdu, A., Li, Z., Zhang, J., & Luo, P. (2025). The Evolving Landscape of Immunotoxicity: Charting Mechanisms and Future Strategies for Immune Checkpoint Inhibitor Adverse Events. Med Research, 1(3), 322-358. https://doi.org/10.1002/mdr2.70019
Vancouver
Lin A, Zheng K, Jiang A, Huang X, Wang Q, Hajdu A, et al. The Evolving Landscape of Immunotoxicity: Charting Mechanisms and Future Strategies for Immune Checkpoint Inhibitor Adverse Events. Med Research. 2025;1(3):322-358. doi:10.1002/mdr2.70019
BibTeX
@article{Lin2025,
author = {Lin, Anqi and Zheng, Keyin and Jiang, Aimin and Huang, Xufeng and Wang, Qi and Hajdu, András and Li, Zhengrui and Zhang, Jian and Luo, Peng},
title = {The Evolving Landscape of Immunotoxicity: Charting Mechanisms and Future Strategies for Immune Checkpoint Inhibitor Adverse Events},
journal = {Med Research},
year = {2025},
volume = {1},
number = {3},
pages = {322--358},
doi = {10.1002/mdr2.70019}
}
EUVIMED